THE WHAT? Macy’s, Inc. delivered stronger-than-expected Q3 2025 results, reporting its highest comparable sales growth in 13 quarters and lifting full-year guidance — including updated Core Adjusted EBITDA expectations of 7.5% to 7.7%, correcting the prior figure of 7.5% to 7.8%.
THE DETAILS Macy’s, Inc. posted Q3 net sales of US$4.7 billion, surpassing internal expectations, while comparable sales rose 2.5% (owned) and 3.2% (O+L+M). All nameplates recorded positive comparable sales, with Bluemercury up 1.1% and maintaining another quarter of growth amid ongoing momentum in prestige beauty.
Bloomingdale’s continued to outperform the group, while Macy’s Reimagine 125 store fleet showed steadier gains than the broader nameplate. Gross margin declined 20bps due to tariff impacts, partly offset by mitigation efforts. SG&A expenses fell US$40 million, reflecting store closures and cost controls.
Macy’s updated full-year guidance includes higher sales and earnings expectations, with Core Adjusted EBITDA now projected at 7.5% to 7.7% of revenue, and Adjusted diluted EPS raised to US$2.00 to US$2.20. Management noted a “more choiceful” consumer in Q4, but expects the company’s financial position and multi-tier brand portfolio — spanning off-price to luxury — to support continued flexibility
THE WHY? Bluemercury’s continued growth and improved customer traffic across Macy’s “go-forward” stores indicate a strengthening environment for prestige beauty and beauty-adjacent retail, underpinned by Macy’s broader operational stabilisation.
Source: businesswire
The post Macy’s Lifts 2025 Outlook as Q3 Beats Expectations; Bluemercury Maintains Growth Streak appeared first on Global Cosmetics News.